PROGNOSIS AFTER RESECTION OF RESIDUAL MASSES FOLLOWING CHEMOTHERAPY FOR METASTATIC NONSEMINOMATOUS TESTICULAR CANCER - A MULTIVARIATE-ANALYSIS

被引:44
作者
STEYERBERG, EW
KEIZER, HJ
ZWARTENDIJK, J
VANRIJK, GL
VANGROENINGEN, CJ
HABBEMA, JDF
STOTER, G
机构
[1] UNIV HOSP LEIDEN, DEPT CLIN ONCOL UROL & THORAC SURG, POB 9600, 2300 RC LEIDEN, NETHERLANDS
[2] ERASMUS UNIV ROTTERDAM, CTR CLIN DECIS SCI, 3000 DR ROTTERDAM, NETHERLANDS
[3] FREE UNIV AMSTERDAM HOSP, DEPT MED ONCOL, 1081 HV AMSTERDAM, NETHERLANDS
[4] ROTTERDAM CANC INST, DEPT MED ONCOL, 3075 EA ROTTERDAM, NETHERLANDS
关键词
D O I
10.1038/bjc.1993.313
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Following chemotherapy for metastatic nonseminomatous testicular cancer, 86 patients with normal serum markers AFP and HCG underwent resection of residual tumour masses (63 laparotomy, 11 thoracotomy, 12 both). Prognostic factors for relapse and survival were analysed with Kaplan-Meier curves and Cox regression analysis. Putative prognostic factors included age, the primary histology, prechemotherapy level of the tumour markers AFP and HCG, the extent of disease (lymph nodes, lung and hepatic metastases) before and after chemotherapy, the histology of the resected material and the completeness of the surgical procedure. Eleven patients relapsed during follow-up (median 47 months), accounting for a 5 year relapse free percentage of 87.4%. Adverse prognostic factors were (1) prechemotherapy level of HCG (greater-than-or-equal-to 10,000 IU l-1; (2) incomplete resection; and (3) the extent of disease, especially of lung metastases (prechemotherapy number less-than-or-equal-to 3,4- 19, greater-than-or-equal-to 20; or size after chemotherapy > 1 cm; or presence of any residual lung metastasis after chemotherapy without residual abdominal metastases). The histology found at resection was not associated with the risk of relapse, which might be explained by the effectiveness of postresection chemotherapy, which in the majority of these patients was a salvage regimen rather than two further cycles of the initial cytostatics. A good and a poor risk group were formed, based on HCG level and completeness of resection. The effect of salvage chemotherapy after resection of viable cancer cells needs further investigation.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 24 条
[1]   PROGNOSTIC FACTORS IN UNSELECTED PATIENTS WITH NONSEMINOMATOUS METASTATIC TESTICULAR CANCER - A MULTICENTER EXPERIENCE [J].
AASS, N ;
KLEPP, O ;
CAVALLINSTAHL, E ;
DAHL, O ;
WICKLUND, H ;
UNSGAARD, B ;
BALDETORP, L ;
AHLSTROM, S ;
FOSSA, SD .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) :818-826
[2]   ASSESSMENT OF RISK IN METASTATIC TESTIS CARCINOMA - IMPACT ON TREATMENT [J].
BAJORIN, DF ;
GELLER, NL ;
BOSL, GJ .
UROLOGIA INTERNATIONALIS, 1991, 46 (03) :298-303
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   COMBINATION CHEMOTHERAPY WITH BLEOMYCIN, ETOPOSIDE AND CISPLATIN (BEP) FOR METASTATIC TESTICULAR TERATOMA - LONG-TERM FOLLOW-UP [J].
DEARNALEY, DP ;
HORWICH, A ;
AHERN, R ;
NICHOLLS, J ;
JAY, G ;
HENDRY, WF ;
PECKHAM, MJ .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (06) :684-691
[5]  
Donohue J P, 1984, Cancer, V54, P2716
[6]   CORRELATION OF COMPUTERIZED TOMOGRAPHIC CHANGES AND HISTOLOGICAL-FINDINGS IN 80 PATIENTS HAVING RADICAL RETROPERITONEAL LYMPH-NODE DISSECTION AFTER CHEMOTHERAPY FOR TESTIS CANCER [J].
DONOHUE, JP ;
ROWLAND, RG ;
KOPECKY, K ;
STEIDLE, CP ;
GEIER, G ;
NEY, KG ;
EINHORN, L ;
WILLIAMS, S ;
LOEHRER, P .
JOURNAL OF UROLOGY, 1987, 137 (06) :1176-1179
[7]   TREATMENT OF TESTICULAR CANCER - A NEW AND IMPROVED MODEL [J].
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) :1777-1781
[8]   IS POSTCHEMOTHERAPY RETROPERITONEAL SURGERY NECESSARY IN PATIENTS WITH NONSEMINOMATOUS TESTICULAR CANCER AND MINIMAL RESIDUAL TUMOR MASSES [J].
FOSSA, SD ;
QVIST, H ;
STENWIG, AE ;
LIEN, HH ;
OUS, S ;
GIERCKSKY, KE .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :569-573
[9]  
GELLER NL, 1989, CANCER-AM CANCER SOC, V63, P440, DOI 10.1002/1097-0142(19890201)63:3<440::AID-CNCR2820630308>3.0.CO
[10]  
2-7